Celgene Corporation: Two Major Phase III Studies Report Oral REVLIMID(R) (Lenalidomide) Plus Dexamethasone Shows Increased Overall Survival Advantage to Dexamethasone Plus Placebo in Previously Treated Multiple Myeloma Patients in The New England Journal

BOUDRY, Switzerland--(BUSINESS WIRE)--The New England Journal of Medicine today published updated clinical data from two Celgene Corporation (NASDAQ: CELG)-sponsored multi-centered, randomized, double-blind, placebo-controlled Phase III pivotal studies evaluating lenalidomide plus dexamethasone in previously treated multiple myeloma patients.